Discontinued — last reported Q4 '25
Accenture Acquisitions increased by 326.4% to $1.59B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 535.6%, from $250.80M to $1.59B. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -22.9% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $429.24M | $2.63B | $1.74B | $113.75M | $363.61M | $1.24B | $686.46M | $390.53M | $257.02M | $1.20B | $788.03M | $2.12B | $2.33B | $1.34B | $241.56M | $250.80M | $297.14M | $681.76M | $373.79M | $1.59B |
| QoQ Change | — | +511.9% | -33.9% | -93.4% | +219.7% | +239.7% | -44.4% | -43.1% | -34.2% | +365.7% | -34.2% | +169.2% | +9.8% | -42.3% | -82.0% | +3.8% | +18.5% | +129.4% | -45.2% | +326.4% |
| YoY Change | — | — | — | — | -15.3% | -53.0% | -60.4% | +243.3% | -29.3% | -3.1% | +14.8% | +443.2% | +806.4% | +12.3% | -69.3% | -88.2% | -87.2% | -49.3% | +54.7% | +535.6% |